Rezolute IncChange company Symbol lookupSelect an option...RZLT Rezolute IncMIRM Mirum Pharmaceuticals IncFCELB Fuelcell Energy IncUK Ucommune International LtdCRDF Cardiff Oncology IncTRNR Interactive Strength IncOMGA Omega Therapeutics IncACST Acasti Pharma IncPYPD PolyPid LtdACRX AcelRx Pharmaceuticals IncGo
Change company Symbol lookup
Select an option...
RZLT Rezolute Inc
MIRM Mirum Pharmaceuticals Inc
FCELB Fuelcell Energy Inc
UK Ucommune International Ltd
CRDF Cardiff Oncology Inc
TRNR Interactive Strength Inc
OMGA Omega Therapeutics Inc
ACST Acasti Pharma Inc
PYPD PolyPid Ltd
ACRX AcelRx Pharmaceuticals Inc
Health Care : Biotechnology | Small Cap Value
Company profileRezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q4 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q4 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced September 14, 2023 | -$0.25 | Q4 Consensus of 5 analysts | -$0.36 | Difference from consensus | 29.78% | Q1 Earnings will announce | (Unconfirmed) November 7, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
RZLT's fiscal year ends in June
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.